The Journal of Clinical Endocrinology & Metabolism· 2026Q1
Diagnostic accuracy study of morning salivary cortisone for screening adrenal insufficiency in a real-world cohort
- 1citations
- Q1SCImago
- 2026year
Short summary
Morning salivary cortisone accurately screens for adrenal insufficiency with an AUC of 0.93, performing comparably to serum cortisol and better than salivary cortisol.
AI-generated from the title and abstract; the full text is not read.
Key points
- Morning salivary cortisone achieved an AUC of 0.93 for predicting adrenal insufficiency, identical to serum cortisol and superior to salivary cortisol (AUC 0.87).
- A salivary cortisone threshold of ≥703 ng/dL (19.5 nmol/L) achieved 97% sensitivity for ruling out adrenal insufficiency.
- A salivary cortisone threshold of <180 ng/dL (5.0 nmol/L) achieved 97% specificity for ruling in adrenal insufficiency.
- An intermediate threshold of <389 ng/dL (10.8 nmol/L) identified patients needing potential glucocorticoid cover.
AI-generated from the title and abstract; the full text is not read.
Abstract
CONTEXT: Morning serum cortisol is used to screen for adrenal insufficiency, but requires venepuncture, early morning clinic attendance, and may be affected by altered corticosteroid-binding globulin (CBG) levels. Salivary cortisone is a non-invasive, home-based alternative. OBJECTIVE: To assess the diagnostic accuracy of morning salivary cortisone for screening adrenal insufficiency and establish clinically relevant thresholds. DESIGN: Retrospective cross-sectional diagnostic accuracy study (2017 to 2024). SETTING: Single tertiary oncology and endocrinology center in the United Kingdom. PARTICIPANTS: Consecutive patients undergoing adrenocorticotropin hormone (ACTH) stimulation test for suspected adrenal insufficiency. INTERVENTION: Salivary sampling for cortisone and cortisol. MAIN OUTCOME MEASURES: Sensitivity and specificity of baseline salivary cortisone. RESULTS: A total of 517 ACTH stimulation tests in 449 participants were included; adrenal insufficiency was confirmed in 104 tests (20.1%). Baseline salivary cortisone accurately predicted adrenal insufficiency (area under the receiver operating characteristic curve [AUC] 0.93, 95% CI [0.91-0.95]), similar to serum cortisol (0.93, 0.90-0.95; p = 0.67) and superior to salivary cortisol (0.87, 0.82-0.91; p = 0.00063). A baseline salivary cortisone rule-out threshold ≥703 ng/dL (19.5 nmol/L) (sensitivity 0.97 [95% CI 0.92-0.99]; specificity 0.59 [0.54-0.63]) and a rule-in threshold <180 ng/dL (5.0 nmol/L) (sensitivity 0.58 [0.48-0.67]; specificity 0.97 [0.95-0.98]) provided the highest net benefit. An intermediate threshold <389 ng/dL (10.8 nmol/L) (sensitivity 0.83 [0.74-0.89]; specificity 0.87 [0.83-0.90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory testing. CONCLUSION: Baseline morning salivary cortisone performs at least as well as serum cortisol for adrenal insufficiency screening.
The authors' abstract, as published at the source. The Journal of Clinical Endocrinology & Metabolism, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine